Pharmaceutical Applications

Size: px
Start display at page:

Download "Pharmaceutical Applications"

Transcription

1 Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients experiencing an AE in each treatment group and include a standard percentage calculation. This standard way of calculating percentage is the number of patients experiencing an AE divided by the number of patients who were randomized to a particular treatment. But in studies with long-term follow-up, this percentage calculation may not be appropriate because there is a potential for differences in the follow-up duration between treatment groups. A more appropriate measure under this scenario is the exposure-adjusted incidence rate. The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure-time among patients in the respective treatment group at risk of an initial occurrence of the event. This paper will explain how to create an "input dataset" that can be used to obtain the standard percentage and exposure adjusted incidence rates with a "one proc away" approach. Introduction Safety is a major indicator for drug approval. When a Clinical Study Report (CSR) is submitted there are a number of tables with AE counts and inferential statistics. The duration of a clinical study can range from a few hours to many years. In studies with long-term follow-up, the standard percentage may not be appropriate because there is a potential for differences in the follow-up duration between treatment groups. Additionally, due to the chemical component of a drug given to the study patients, the clinician may desire to identify other defined AE events known as special interest AEs; i.e., those adverse events which are not usually a part of the standard AE dataset. For example, a special interest AE table may require information from domains not of direct concern to the study. These special interest AE events also can be categorized as Tier 1 AE's; some of these AE's are comprised of one or more associated incidents defined in the protocol. This paper focuses on the concept of creating an analysis ready dataset for both standard percentage and exposure adjusted special interest AEs. This is especially important when the information for the special interest events dataset comes from different domains. Objective The objective of this paper is to show how easy it is to create a dataset that can be used to output desired study results such as frequencies, proportions, AE rates and p-values using a one proc away method. 1

2 Procedure with an Example Throughout the paper special interest AEs are referred to as EVENTS and the AE incidences associated with those EVENTS are referred to as EVNTTERM. Figure 1 is the mock-up that illustrates the outcome of producing the dataset being discussed here. You can see how events and evntterms and the corresponding statistics are displayed. Figure 1 Number (%) of Patients with Special Interest AE 's by Treatment Group All Treated Patients Number (%) of AE Difference in Proportion of AE AE Rates Per Patient-years of Exposure TRT1 TRT2 TRT1 minus TRT2 TRT1 TRT2 XXX XXX Diff. (95% CI ) p-value With Diabetes xx(x.x) xx(x.x) x.x(x.x,x.x).xxx.xxx.xxx Anti-diabetic medications xx(x.x) xx(x.x) x.x(x.x,x.x) Elevations of Fasting xx(x.x) xx(x.x) x.x(x.x,x.x) Diabetes mellitus xx(x.x) xx(x.x) x.x(x.x,x.x) type 2 mellitus xx(x.x) xx(x.x) x.x(x.x,x.x) With worsening xx(x.x) xx(x.x) x.x(x.x,x.x).xxx.xxx.xxx Tolerances Fasting >100 xx(x.x) xx(x.x) x.x(x.x,x.x) Consecutive Elevations of xx(x.x) xx(x.x) x.x(x.x,x.x) Fasting Hyperglycemia xx(x.x) xx(x.x) x.x(x.x,x.x) Blood increased xx(x.x) xx(x.x) x.x(x.x,x.x) CI = Confidence intervals. Calculated using a method based on Wilson's score method. p-values are from Fisher's Exact test. AE rates per patient-years of exposure = (number of patients with AE/sum of days at risk for AE) x days/year. The following section explains how to create a dataset in such a way as to get all the information needed for reporting the desired statistics. 2

3 STEP 1 Identifying EVENTS: How many events are specified in the protocol? What event terms are associated with an event? The answers to these questions are determined by clinicians and are included in the study protocol. If there are 10 events to be included in the desired table then it is necessary to precisely understand what they are and how they are defined. For easy programming assign a numeric code to each event. For example, when there are only three events the numeric code would be 1= ' Diabetes' 2 = 'Worsening Tolerances' 3= 'ALT/AST elevations with muscle symptoms' Look at the hypothetical example in Figure 1 above, "Diabetes" is an event of interest and event terms are then listed as associated event terms for the main event. In this figure the event terms are "anti medication" taken from the CM (Concomitant Medications) domain, OR "elevations of fasting glucose" taken from the LB (Lab) domain OR "any AE s related to " (terms should be defined) taken from the AE domain. At this stage it is important to understand how the conditions of associated event terms are combined. The combinations could be either "OR", "AND", or both. Depending on the conditions for event terms the set or merge statements should be applied in order to reflect the conditions. Another hypothetical example: "Worsening of Tolerance" can be another event of interest. It can be defined as "not on anti-diabetic medications during pre treatment period" from CM domain AND "no medical history of " from MH (Medical History) domain AND "baseline Fasting glucose < 100" from LB domain AND "no onset terms" defined from AE domain AND "on treatment fasting >100" OR "two consecutive fasting glucose elevations" from LB domain OR "any terms related to indicate glucose tolerances" from AE domain. STEP 2 The next step is to capture the necessary information from each domain related to the incidents of interest. Make sure all the event dates are within the range defined in the protocol. The data should appear as in Figure 2 after assembling the data from each domain. 3

4 STEP 3 The following code captures the first incidence of each unique event term. Proc sort data=event; by subjid evntterm evntdt; - data event1; set event; by subjid evntterm evntdt; If first.evntterm; termfl =1; flag the unique associated event term per patient. Figure 2 EVENT dataset SUBJECT EVENT EVNTDT EVNTTERM EVNTCODE EVNTVALU 101 Diabetes 02/05/10 anti diabetic 1 1 medication 101 Diabetes 02/07/10 anti diabetic 1 1 medication 101 Diabetes 01/12/10 anti diabetic 1 1 medication 101 Diabetes 01/12/10 Increasing Diabetes 01/10/10 Increasing Diabetes 01/29/10 mellitus Diabetes 01/05/10 mellitus Diabetes 02/12/10 insulin resistant Diabetes 02/15/10 type mellitus 101 Diabetes 01/04/10 type mellitus 104 Diabetes 05/09/10 Increasing Diabetes 06/03/10 insulin resistant Diabetes 06/10/10 latent 1 1 autoimmune 104 Diabetes 07/02/10 latent autoimmune 1 1 4

5 The above sorting criteria should be applied for each event with associated event terms. Once we append all events you will have a dataset with all events and their associated event terms. The question then arises as to how we can get AE rates for each of the events? AE rates are calculated by summing all events (Yes, No) and dividing by sum of the times to the first event in the case of those subjects with an AE plus the total exposure of those reporting no event. It becomes evident that in order to do the AE rate calculations we need to find the patients who are included in the denominator but did not have any events. Briefly on needs to get the unique patients that will be in the denominator and create EVENTS dummies for them. If there are 10 EVENTS for each patient then the code that creates the set of dummies is: STEP 4 proc sort data=derived.adsl out=adme; by subjid; data dummy; set adme; by subjid; do evntcode = 1 to 10; output; end; Merge data set that was created for the event terms and merge with the just created dummy dataset by subjid and evntcode in order to assign event for each patient. STEP 5 data allevent; merge event(in=b)dummy(in=a) ; by subjid evntcode; if a and not b then evntvalu=0; <- assigning 0 when there are no any events. Apply this condition to capture the duration of the staying on the study for patients if evntvalu = 1 then toevent = (evntdt -stsdt)/365.25; if evntvalu= 0 then toevent = (stedt - stsdt)/365.25;. 5

6 STEP 6 Data tmevnt; set allevent; by an evntcode evntdt; if first.evntcode then evntfl = 1; <- this captures the first date of the event for each patient The final dataset with selected variables should appear as shown in Figure 3 Figure 3 SUBJID EVENT EVNTDT EVNTTERM EVNTCODE EVNTVALU EVNTFL TERMFL 101 Diabetes 01/04/10 Type Diabetes mellitus 101 Diabetes 01/05/10 Diabetes mellitus 101 Diabetes 01/10/10 Increasing Diabetes 01/12/10 Anti medication 101 Diabetes 02/12/10 Insulin resistant Diabetes Diabetes Diabetes 05/09/10 Increasing Diabetes 06/03/10 Insulin resistant Diabetes 06/10/10 Latent autoimmune 101 FG Tolerances 03/08/2010 FG > FG Tolerances 04/11/ Hyperglycemia 102 FG Tolerances 06/20/2010 Blood Increase 102 FG Tolerances 06/27/2010 Hyperglycemia FG Tolerances 01/22/2010 Consecutive elevation of FG 103 FG Tolerances 02/02/2010 Blood Increase 103 FG Tolerances 03/12/2010 Hyperglycemia FG Tolerances

7 Why is this process one proc away? With this simple code AE counts and rates for each EVENTS can be produced. proc sql; create table ae2 as select distinct evntcode, trtmnt, sum(evntvalu) as COUNTS counts for each event,put (round(sum(evntvalu)/sum(toevent),.001), 5.3) as AERATES from tmevnt where evntfl=1 group by trtmnt, evntcode order by evntcode; quit; After running the code you will have an output dataset as shown in Figure 4 Figure 4 TRTMNT EVNTCODE COUNTS AERATES TRT TRT TRT TRT TRT TRT TRT TRT TRT TRT Getting counts for each of the associated terms under each of the events is simple: proc freq data=tmevnt ; where evntterm ne ' ' and termfl=1; /*counts for each evntterm by evntcode and trtmnt*/ tables evntcode*evntterm*trtmnt/out=fterms; Make sure all the patients in the denominator are in the main dataset Finally, after making sure of the proper subsetting, the p-values for each event are computed as: proc freq data=tmevnt; where evntfl=1; tables evntcode*trtmnt*evntvalu/ exact fisher ; ods output FishersExact=fishall(where=(NAME1='XP2_FISH')); 7

8 Conclusion In this paper we considered the specific example of creating a one proc away dataset for the presentation of specific interest AE tables. There are certain ways in which a programmer can create datasets to produce desired results. The most important thing to understand is the specific result that we need to produce and how can it be done efficiently without any manipulations in the tables program. Two essential features are common to all one proc away datasets. First, there must be clear dataset specifications. Second, there must be clear mock-ups for the tables. If the one proc away datasets are analysis ready then the whole analytical process is efficient and can save a lot of time. References SAS Institute Inc. 2004, SQL Processing with SAS Course Notes Acknowledgments Thank you to Ram Radhakrishnan for reviewing this work and providing constructive feedback. AUTHOR CONTACT Your comments and questions are valued and welcome. Contact the author at: Pushpa Saranadasa Phone: (267) Pushpa_saranadasa@merck.com SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. 8

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep

More information

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

Programmatic Challenges of Dose Tapering Using SAS

Programmatic Challenges of Dose Tapering Using SAS ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In

More information

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd. PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables

More information

PharmaSUG Paper QT38

PharmaSUG Paper QT38 PharmaSUG 2015 - Paper QT38 Statistical Review and Validation of Patient Narratives Indrani Sarkar, inventiv Health Clinical, Indiana, USA Bradford J. Danner, Sarah Cannon Research Institute, Tennessee,

More information

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS

More information

Imputing Dose Levels for Adverse Events

Imputing Dose Levels for Adverse Events Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing

More information

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro SESUG 2016 Paper CC-160 Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro Lifang Zhang, Department of Biostatistics and Epidemiology, Augusta University ABSTRACT SAS software

More information

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints Collapsing Longitudinal Data Across Related Events and Imputing Endpoints James Joseph, INC Research, King of Prussia, PA INTRODUCTION When attempting to answer a research question, the best study design

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION Adaptive Randomization: Institutional Balancing Using SAS Macro Rita Tsang, Aptiv Solutions, Southborough, Massachusetts Katherine Kacena, Aptiv Solutions, Southborough, Massachusetts ABSTRACT Adaptive

More information

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies T07-2008 Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies Daojun Mo 1, Xia Li 2 and Alan Zimmermann 1 1 Eli Lilly and Company, Indianapolis, IN 2 inventiv Clinical

More information

OCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016

OCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016 OCCDS Creating flags or records Rob Wartenhorst PhUSE Barcelona 2016 Introduction ADAE, ADCM and ADMH originally set up using ADAE structure. After release of OCCDS guide attempted to implement the occurrence

More information

Implementing Worst Rank Imputation Using SAS

Implementing Worst Rank Imputation Using SAS Paper SP12 Implementing Worst Rank Imputation Using SAS Qian Wang, Merck Sharp & Dohme (Europe), Inc., Brussels, Belgium Eric Qi, Merck & Company, Inc., Upper Gwynedd, PA ABSTRACT Classic designs of randomized

More information

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. Paper SP02 Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. José Luis Jiménez-Moro (PharmaMar, Madrid, Spain) Javier Gómez (PharmaMar, Madrid, Spain) ABSTRACT

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ

Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ ABSTRACT The challenge of creating multiple cohorts of people within a data set, based on

More information

Guidelines for HCHS/SOL Manuscript Verification Version 1.0 (August 14, 2012)

Guidelines for HCHS/SOL Manuscript Verification Version 1.0 (August 14, 2012) Guidelines for HCHS/SOL Manuscript Verification Version 1.0 (August 14, 2012) Introduction Commonly accepted best practices in the biostatistics field include the independent verification of the data management

More information

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However,

More information

Stata: Merge and append Topics: Merging datasets, appending datasets - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1. Terms There are several situations when working with

More information

PharmaSUG China 2018 Paper SP-28

PharmaSUG China 2018 Paper SP-28 PharmaSUG China 2018 Paper SP-28 SAS Macros for the Area Under the Curve (AUC) Calculation of Continuous Glucose Monitoring (CGM) Data Xiao Ran Han, The Chinese University of Hong Kong, China Ka Chun Chong,

More information

What Are Your Odds? : An Interactive Web Application to Visualize Health Outcomes

What Are Your Odds? : An Interactive Web Application to Visualize Health Outcomes What Are Your Odds? : An Interactive Web Application to Visualize Health Outcomes Abstract Spreading health knowledge and promoting healthy behavior can impact the lives of many people. Our project aims

More information

Standards for Analyzable Submission Datasets for Directed Safety Analyses

Standards for Analyzable Submission Datasets for Directed Safety Analyses Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com

More information

HUNGER-RELIEF ORGANIZATION TOOLKIT

HUNGER-RELIEF ORGANIZATION TOOLKIT HUNGER-RELIEF ORGANIZATION TOOLKIT Contents Welcome to the #GiveHealthy Movement! 2 What s your role as a #GiveHealthy organization? 2 Why should your organization join the #GiveHealthy Movement? 2 How

More information

Does factor indeterminacy matter in multi-dimensional item response theory?

Does factor indeterminacy matter in multi-dimensional item response theory? ABSTRACT Paper 957-2017 Does factor indeterminacy matter in multi-dimensional item response theory? Chong Ho Yu, Ph.D., Azusa Pacific University This paper aims to illustrate proper applications of multi-dimensional

More information

Improved Transparency in Key Operational Decisions in Real World Evidence

Improved Transparency in Key Operational Decisions in Real World Evidence PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International

More information

ADaM Tips for Exposure Summary

ADaM Tips for Exposure Summary ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary

More information

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial Christoph Gerlinger * and Ursula Franke ** * Laboratoires Fournier S.C.A. and ** biodat

More information

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps

More information

BOOKLET ONE. Introduction to Behavioural Activation for Depression

BOOKLET ONE. Introduction to Behavioural Activation for Depression BEHAVIOURAL ACTIVATION FOR DEPRESSION BOOKLET ONE Introduction to Behavioural Activation for Depression Contents Missing sources of wellbeing 2-3 Sources of misery 4-5 What we do when we feel down 6-7

More information

BlueBayCT - Warfarin User Guide

BlueBayCT - Warfarin User Guide BlueBayCT - Warfarin User Guide December 2012 Help Desk 0845 5211241 Contents Getting Started... 1 Before you start... 1 About this guide... 1 Conventions... 1 Notes... 1 Warfarin Management... 2 New INR/Warfarin

More information

Kick It Old School - Creating Reports with the DATA _NULL_ Step

Kick It Old School - Creating Reports with the DATA _NULL_ Step Kick It Old School - Creating Reports with the DATA _NULL_ Step Sai Ma, PharmaNet/i3, Toronto, Ontario Canada Suwen Li, Everest Clinical Research Services Inc., Markham, Ontario Canada Minlan Li, Everest

More information

Generate Informative Clinical Laboratory Results Listing

Generate Informative Clinical Laboratory Results Listing PharmaSUG2011 - Paper PO02 Generate Informative Clinical Laboratory Results Listing Sai Ma, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT Clinical laboratory results review

More information

Introduction to SPSS S0

Introduction to SPSS S0 Basic medical statistics for clinical and experimental research Introduction to SPSS S0 Katarzyna Jóźwiak k.jozwiak@nki.nl November 10, 2017 1/55 Introduction SPSS = Statistical Package for the Social

More information

A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia

A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia Paper 109 A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia ABSTRACT Meta-analysis is a quantitative review method, which synthesizes

More information

Frequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß

Frequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß Frequency Tables Aspects to Consider 15.10.2014 / PhUSE - Industry Starters / Katja Glaß Agenda Introduction Do the double programming Demography Adverse Events Laboratory Summary and further aspects Page

More information

Using CDISC Models for the Analysis of Safety Data

Using CDISC Models for the Analysis of Safety Data Paper RA02 Using CDISC Models for the Analysis of Safety Data Susan J. Kenny, Inspire Pharmaceuticals Inc. Research Triangle Park, NC, USA Edward D. Helton, SAS Institute, Cary, NC, USA ABSTRACT The collection

More information

Let s get started with the OneTouch Reveal web app

Let s get started with the OneTouch Reveal web app Let s get started with the Step-by-Step Guide Your step-by-step guide to setting up and using the with the OneTouch Reveal mobile app The supporting you and your patients throughout their journey Designed

More information

Inpatient Insulin: A Team Approach

Inpatient Insulin: A Team Approach Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/inpatient-insulin-a-team-approach/3763/

More information

This report summarizes the stakeholder feedback that was received through the online survey.

This report summarizes the stakeholder feedback that was received through the online survey. vember 15, 2016 Test Result Management Preliminary Consultation Online Survey Report and Analysis Introduction: The College s current Test Results Management policy is under review. This review is being

More information

mehealth for ADHD Parent Manual

mehealth for ADHD Parent Manual mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers

More information

Lab 8: Multiple Linear Regression

Lab 8: Multiple Linear Regression Lab 8: Multiple Linear Regression 1 Grading the Professor Many college courses conclude by giving students the opportunity to evaluate the course and the instructor anonymously. However, the use of these

More information

Using the NWD Integrative Screener as a Data Collection Tool Agency-Level Aggregate Workbook

Using the NWD Integrative Screener as a Data Collection Tool Agency-Level Aggregate Workbook Using the NWD Integrative Screener as a Data Collection Tool Agency-Level Aggregate Workbook The NWD Integrative Screener was designed to be user friendly for providers and agencies. Many items and health

More information

Analysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data

Analysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data Analysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data 1. Purpose of data collection...................................................... 2 2. Samples and populations.......................................................

More information

Baseline Mean Centering for Analysis of Covariance (ANCOVA) Method of Randomized Controlled Trial Data Analysis

Baseline Mean Centering for Analysis of Covariance (ANCOVA) Method of Randomized Controlled Trial Data Analysis MWSUG 2018 - Paper HS-088 Baseline Mean Centering for Analysis of Covariance (ANCOVA) Method of Randomized Controlled Trial Data Analysis Jennifer Scodes, New York State Psychiatric Institute, New York,

More information

2017 Medicare CAHPS At-A-Glance Report

2017 Medicare CAHPS At-A-Glance Report 2017 Medicare CAHPS At-A-Glance Report CMS MA PD Contract: H9207 Project Number(s): 30120117 and 10123759 Current data as of: 07/10/2017 1965 Evergreen Boulevard Suite 100, Duluth, Georgia 30096 2017 At-A-Glance

More information

GLUTEN-FREE FOOD SCHEME. Information Pack

GLUTEN-FREE FOOD SCHEME. Information Pack GLUTEN-FREE FOOD SCHEME Information Pack The Tayside Gluten-Free Food Scheme is part of the Scottish Gluten-Free Food Service. There are variations from the Scottish Service and more information can be

More information

Do the sample size assumptions for a trial. addressing the following question: Among couples with unexplained infertility does

Do the sample size assumptions for a trial. addressing the following question: Among couples with unexplained infertility does Exercise 4 Do the sample size assumptions for a trial addressing the following question: Among couples with unexplained infertility does a program of up to three IVF cycles compared with up to three FSH

More information

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT

More information

SHARED DECISION MAKING WORKSHOP SMALL GROUP ACTIVITY LUNG CANCER SCREENING ROLE PLAY

SHARED DECISION MAKING WORKSHOP SMALL GROUP ACTIVITY LUNG CANCER SCREENING ROLE PLAY SHARED DECISION MAKING WORKSHOP LUNG CANCER SCREENING ROLE PLAY Instructions Your group will role play a Shared Decision Making (SDM) conversation around lung cancer screening using the provided scenario.

More information

Evaluation: Controlled Experiments. Title Text

Evaluation: Controlled Experiments. Title Text Evaluation: Controlled Experiments Title Text 1 Outline Evaluation beyond usability tests Controlled Experiments Other Evaluation Methods 2 Evaluation Beyond Usability Tests 3 Usability Evaluation (last

More information

Registered Radiologist Assistant (R.R.A. ) 2016 Examination Statistics

Registered Radiologist Assistant (R.R.A. ) 2016 Examination Statistics Registered Radiologist Assistant (R.R.A. ) Examination Statistics INTRODUCTION This report summarizes the results of the Registered Radiologist Assistant (R.R.A. ) examinations developed and administered

More information

Making comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups

Making comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups Making comparisons Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups Data can be interpreted using the following fundamental

More information

Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA

Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA PharmaSUG 2014 - Paper SP08 Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA ABSTRACT Randomized clinical trials serve as the

More information

2016 Children and young people s inpatient and day case survey

2016 Children and young people s inpatient and day case survey NHS Patient Survey Programme 2016 Children and young people s inpatient and day case survey Technical details for analysing trust-level results Published November 2017 CQC publication Contents 1. Introduction...

More information

WHY NEW MEMBERSHIP OFFERINGS AND WHO DECIDED ON THE CHANGE

WHY NEW MEMBERSHIP OFFERINGS AND WHO DECIDED ON THE CHANGE WHY NEW MEMBERSHIP OFFERINGS AND WHO DECIDED ON THE CHANGE Why are these changes being made? As the landscape of member organizations continues to change, to remain relevant to shifts in our profession,

More information

ADDRESSING CHRONIC DISEASES

ADDRESSING CHRONIC DISEASES ADDRESSING CHRONIC DISEASES Health-Management Strategies for Use with Behavioral Health Clients Mary Brunette, MD Delia Cimpean Hendrick, MD SCOPE AND SEQUENCE For more information about this program,

More information

Introducing DIA-TEC CLOUDTM. Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM

Introducing DIA-TEC CLOUDTM. Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM Introducing DIA-TEC CLOUDTM Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM Technology. Education. Community. Diabetes happens in real time. Now,

More information

It s time to TALK Targets A guide on using TALK Targets with your patients

It s time to TALK Targets A guide on using TALK Targets with your patients It s time to TALK Targets A guide on using TALK Targets with your patients The TALK Targets campaign was initiated and fully funded by Novo Nordisk. 2 TALK Targets is a patient support campaign for people

More information

V-Go : Simple to start, easy to use

V-Go : Simple to start, easy to use V-Go : Simple to start, easy to use Patient Start Guide Make multiple daily insulin shots a thing of the past. Take control with V-Go. V-Go Customer Care personalized 1-on-1 support for you Call 1-866-881-1209

More information

The Epidemic Model 1. Problem 1a: The Basic Model

The Epidemic Model 1. Problem 1a: The Basic Model The Epidemic Model 1 A set of lessons called "Plagues and People," designed by John Heinbokel, scientist, and Jeff Potash, historian, both at The Center for System Dynamics at the Vermont Commons School,

More information

Lev Sverdlov, Ph.D.; John F. Noble, Ph.D.; Gabriela Nicolau, Ph.D. Innapharma, Inc., Upper Saddle River, NJ

Lev Sverdlov, Ph.D.; John F. Noble, Ph.D.; Gabriela Nicolau, Ph.D. Innapharma, Inc., Upper Saddle River, NJ THE RESULTS OF CLUSTER ANALYSIS OF CLINICAL DATA USING THE FASTCLUS PROCEDURE Lev Sverdlov, Ph.D.; John F. Noble, Ph.D.; Gabriela Nicolau, Ph.D. Innapharma, Inc., Upper Saddle River, NJ ABSTRACT The objective

More information

Review of compliance. Mercia Care Homes Limited Sefton Park. South West. Region: Sefton Park 10 Royal Crescent Weston-super-Mare Somerset BS23 2AX

Review of compliance. Mercia Care Homes Limited Sefton Park. South West. Region: Sefton Park 10 Royal Crescent Weston-super-Mare Somerset BS23 2AX Review of compliance Mercia Care Homes Limited Sefton Park Region: Location address: Type of service: South West Sefton Park 10 Royal Crescent Weston-super-Mare Somerset BS23 2AX Residential substance

More information

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried

More information

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

Treatment Adaptive Biased Coin Randomization: Generating Randomization Sequences in SAS

Treatment Adaptive Biased Coin Randomization: Generating Randomization Sequences in SAS Adaptive Biased Coin Randomization: OBJECTIVES use SAS code to generate randomization s based on the adaptive biased coin design (ABCD) must have approximate balance in treatment groups can be used to

More information

Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality

Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Week 9 Hour 3 Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Stat 302 Notes. Week 9, Hour 3, Page 1 / 39 Stepwise Now that we've introduced interactions,

More information

Application Highlights. Sample Reports.

Application Highlights. Sample Reports. Application Highlights -- Dashboard -- Activity Summary -- Therapy Timeline -- Blood Glucose Trends -- Pump Settings -- Save and Share Sample Reports www.tandemdiabetes.com/tconnect Dashboard Helps you

More information

Evaluation: Scientific Studies. Title Text

Evaluation: Scientific Studies. Title Text Evaluation: Scientific Studies Title Text 1 Evaluation Beyond Usability Tests 2 Usability Evaluation (last week) Expert tests / walkthroughs Usability Tests with users Main goal: formative identify usability

More information

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: All patients

More information

CARE Cross-project Collectives Analysis: Technical Appendix

CARE Cross-project Collectives Analysis: Technical Appendix CARE Cross-project Collectives Analysis: Technical Appendix The CARE approach to development support and women s economic empowerment is often based on the building blocks of collectives. Some of these

More information

A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method

A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

The Spine Institute for Quality Conservative Care QCDR, Powered by Premier, Inc.

The Spine Institute for Quality Conservative Care QCDR, Powered by Premier, Inc. The Spine Institute for Quality Conservative Care QCDR, Powered by Premier, Inc. 2018 non-mips Measure Specifications Last updated March 7, 2018 SPINEIQ5: Change in Functional Outcomes- National Quality

More information

Outcome Measure Considerations for Clinical Trials Reporting on ClinicalTrials.gov

Outcome Measure Considerations for Clinical Trials Reporting on ClinicalTrials.gov Outcome Measure Considerations for Clinical Trials Reporting on ClinicalTrials.gov What is an Outcome Measure? An outcome measure is the result of a treatment or intervention that is used to objectively

More information

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,

More information

Chapter 13 Estimating the Modified Odds Ratio

Chapter 13 Estimating the Modified Odds Ratio Chapter 13 Estimating the Modified Odds Ratio Modified odds ratio vis-à-vis modified mean difference To a large extent, this chapter replicates the content of Chapter 10 (Estimating the modified mean difference),

More information

Consultation on renaming the Local anaesthetics and Prescription only medicines annotations for chiropodists / podiatrists

Consultation on renaming the Local anaesthetics and Prescription only medicines annotations for chiropodists / podiatrists Consultation on renaming the Local anaesthetics and Prescription only medicines annotations for chiropodists / podiatrists 1. Introduction 1.1 We are the Health and Care Professions Council (HCPC). This

More information

CQC s plans for the questions it asks NHS patients

CQC s plans for the questions it asks NHS patients CQC s plans for the questions it asks NHS patients Easy read (May 2016) This is an easy read version of the document Consultation: CQC s NHS Patient Survey Programme (May 2016). It asks you questions about

More information

Simple Linear Regression One Categorical Independent Variable with Several Categories

Simple Linear Regression One Categorical Independent Variable with Several Categories Simple Linear Regression One Categorical Independent Variable with Several Categories Does ethnicity influence total GCSE score? We ve learned that variables with just two categories are called binary

More information

Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to

Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to Decrease and prevent intrusive or troubling feelings and behaviours Increase personal empowerment Improve

More information

Getting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite

Getting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite Getting Started with Insulin Pump Therapy for the MiniMed 530G with Enlite Learning Guide PUMP Foundations MiniMed 530G Insulin Pump Settings Form: We recommend that you record all settings on this form

More information

Automated Immunization Evaluation Process

Automated Immunization Evaluation Process University of Medicine and Dentistry of New Jersey - University of Pennsylvania New Jersey Comprehensive Immunization Program (NJ-CIP) Automated Immunization Evaluation Process Working Paper rev. May 11,

More information

@ Lipitor And Type 2 Diabetes?? Diabetes Symptoms Skin treatment options we have to control diabetes to Meal Plan; Type 1 Diabetes Diet Menu;

@ Lipitor And Type 2 Diabetes?? Diabetes Symptoms Skin treatment options we have to control diabetes to Meal Plan; Type 1 Diabetes Diet Menu; Living With Diabetes Type1 Or Type 2: The Symptoms, Diagnosis & Treatment Of Diabetes: ( Diabetes Meal Planning, Type 2 Diabetes, Diabetes For Dummies, Diabetes Control, Diabetes Diet, Treatment) By Michael

More information

4/14/2016. Take ownership of the care - This is my patient!

4/14/2016. Take ownership of the care - This is my patient! Guidelines and Training in how to be a Emergency Health Professional NAVIGATOR 2016 Paul Stiegler MD FACEP Medical Director EMD Dane County PSCC Onstar LLC Take ownership of the care - This is my patient!

More information

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information. Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement

More information

Study Participants HbA1c (%, mean and SD) Duration of diabetes (years, mean and SD) Age (years, mean and SD) Type 1 diabetes

Study Participants HbA1c (%, mean and SD) Duration of diabetes (years, mean and SD) Age (years, mean and SD) Type 1 diabetes Supplementary Table 1. Baseline characteristics of the included studies and participants Name (year) Type 1 diabetes Length (mths) (2013) 14 6 I:63 C:64 (2010) 15 6 I:67 C:63 Charpentier et al. (2013)

More information

For patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH

For patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority

More information

Numerical Integration of Bivariate Gaussian Distribution

Numerical Integration of Bivariate Gaussian Distribution Numerical Integration of Bivariate Gaussian Distribution S. H. Derakhshan and C. V. Deutsch The bivariate normal distribution arises in many geostatistical applications as most geostatistical techniques

More information

Biostatistics and Design of Experiments Prof. Mukesh Doble Department of Biotechnology Indian Institute of Technology, Madras

Biostatistics and Design of Experiments Prof. Mukesh Doble Department of Biotechnology Indian Institute of Technology, Madras Biostatistics and Design of Experiments Prof Mukesh Doble Department of Biotechnology Indian Institute of Technology, Madras Lecture 02 Experimental Design Strategy Welcome back to the course on Biostatistics

More information

The FASTCLUS Procedure as an Effective Way to Analyze Clinical Data

The FASTCLUS Procedure as an Effective Way to Analyze Clinical Data The FASTCLUS Procedure as an Effective Way to Analyze Clinical Data Lev Sverdlov, Ph.D., Innapharma, Inc., Park Ridge, NJ ABSTRACT This paper presents an example of the fast cluster analysis (SAS/STAT,

More information

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

Step 3 Tutorial #3: Obtaining equations for scoring new cases in an advanced example with quadratic term

Step 3 Tutorial #3: Obtaining equations for scoring new cases in an advanced example with quadratic term Step 3 Tutorial #3: Obtaining equations for scoring new cases in an advanced example with quadratic term DemoData = diabetes.lgf, diabetes.dat, data5.dat We begin by opening a saved 3-class latent class

More information

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research Integrated ADSL PhUSE 2012-10-17 Nate Freimark/Thomas Clinch Theorem Clinical Research ADSL - Not Without Challenges Where to Begin Source Data One ADSL or Two Number of Records per Subject Update or Create

More information

myphonak app User Guide

myphonak app User Guide myphonak app User Guide Getting started myphonak is an app developed by Sonova, the world leader in hearing solutions based in Zurich, Switzerland. Read the user instructions thoroughly in order to benefit

More information

In-hospital Intensive Care Unit Mortality Prediction Model

In-hospital Intensive Care Unit Mortality Prediction Model In-hospital Intensive Care Unit Mortality Prediction Model COMPUTING FOR DATA SCIENCES GROUP 6: MANASWI VELIGATLA (24), NEETI POKHARNA (27), ROBIN SINGH (36), SAURABH RAWAL (42) Contents Impact Problem

More information

A Group Representative s Guide to the Virginia Area Assembly

A Group Representative s Guide to the Virginia Area Assembly Al-Anon Family Groups, Area 57 A Group Representative s Guide to the Virginia Area Assembly Revised Oct. 8, 2017 Table of Contents Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Assembly Definition Assembly

More information

Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study

Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study PharmaSUG 2018 - Paper RW-02 Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study Julia Skinner and Ryan May, Emmes Corporation ABSTRACT Electronic diary (ediary) mobile

More information

Welcome back to our program!

Welcome back to our program! Welcome back to our program! 1 As you likely recall, the SBIRT TIPS training program is a federally funded project that aims to both educate practitioner students and impact health systems. 2 Let s start

More information

Best practices for a successful wellness screening program

Best practices for a successful wellness screening program Health & Wellness Best practices for a successful wellness screening program Identify risk. Increase engagement. Incite change. Identifying health risks in your employee population People at risk for chronic

More information

Modernizing the Mitral Valve: Advances in Robotic and Minimally Invasive Cardiac Repair

Modernizing the Mitral Valve: Advances in Robotic and Minimally Invasive Cardiac Repair Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/modernizing-mitral-valveadvances-robotic-minimally-invasive-cardiac-repair/7686/

More information